At RxSpark we believe prescription drugs and medication should be accessible and affordable for all Americans. In addition to the savings, discounts, and convenience that RxSpark provides, the RxSpark Blog is here to bring you information, news, current events, and important upates on topics that affect healthcare and prescription drugs. Be sure to check back frequently for updates, and if you find any information that is particularly helpful please don't hesitate to share!

Aurobindo’s generic Seroquel XR receives FDA approval

Aurobindo Pharma has received U.S. Food and Drug Administration approval for its quetiapine fumarate extended-release tablets (50mg, 150mg, 200mg, 300mg, and 400mg). The medication is a bioequivalent of the AstraZeneca drug Seroquel XR and is therapeutically equivalent to this product. <br /> Quetia...

Read More

FDA approves first nebulized LAMA treatment for COPD

The U.S. Food and Drug Administration (FDA) has approved Sunovion’s Lonhala Magnair (glycopyrrolate), making it the first nebulized long-acting muscarinic antagonist (LAMA) treatment in the United States for patients with chronic obstructive pulmonary disease (COPD). It is expected to appear i...

Read More

Fiasp: New Rapid-Acting Mealtime Insulin Approved by FDA

Adults with type 1 or type 2 diabetes have a new treatment option available to them following the U.S. Food and Drug Administration’s (FDA) decision to approve Novo Nordisk's rapid-acting mealtime insulin Fiasp (insulin aspart). <br /> The drug is indicated to improve glycemic control in adult...

Read More

Sutent approved by FDA to reduce risk of recurrent kidney cancer

The U.S. Food and Drug Administration (FDA) has extended the approval of Pfizer’s drug Sutent (sunitinib malate) as an adjuvant treatment for adults at a high risk of experiencing a return of renal cell carcinoma following the removal of a kidney. <br /> Adjuvant therapies are treatments follo...

Read More

Juluca: New two drug HIV treatment approved by FDA

The U.S. Food and Drug Administration (FDA) has approved the first once-daily, two-drug single pill treatment for certain patients with human immunodeficiency virus type 1 (HIV-1). Approval for Juluca (dolutegravir and rilpivirine) was granted to ViiV Healthcare, a global specialist in HIV owned by ...

Read More